Shots:
- LCB to receive up front & milestone of ~$1027.5M upon achievement of development & regulatory milestones along with royalties on net sales. The deals also include ~$29.5M in upfront & milestones
- Sotio to get rights to use LCB’s ADC technology for 5 therapeutic programs targeting distinct tumor-associated antigens & will lead research, development, manufacturing & commercialization of ADC products. LCB will be responsible for the research activities & manufacturing of components related to its ConjuAll & linker-payload technologies
- The agreement will combine SOTIO’s antibodies with LCB’s technologies with its multiple different payloads to deliver novel therapeutics for solid tumors
Click here to read the full press release/ article | Ref: Globe Newswire | Image: Biztweet
The post Sotio Signs a Multiple Agreement with LegoChem Biosciences to Develop Novel Therapeutics for the Treatment of Solid Tumors first appeared on PharmaShots.
